<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04525001</url>
  </required_header>
  <id_info>
    <org_study_id>PAR scores</org_study_id>
    <nct_id>NCT04525001</nct_id>
  </id_info>
  <brief_title>MOGGE PAR Scores for Prediction of Outcomes of PAS</brief_title>
  <acronym>PAR</acronym>
  <official_title>MOGGE PAR-A and PAR-P Scores for Prediction of Adverse Outcomes of Placenta Accreta Spectrum: A Multi-center International Validation Study Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Middle-East OBGYN Graduate Education Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Placenta accreta spectrum (PAS) is a set of placentation disorders that are associated with&#xD;
      trophoblastic invasion through the physiologic decidual-myometrial junction zone. PAS may be&#xD;
      associated with massive obstetric hemorrhage, surgical injuries, maternal intensive care unit&#xD;
      (ICU) admission, reoperation, and prolonged hospitalization.&#xD;
&#xD;
      This study aims at estimating the validity of &quot;MOGGE placenta accreta risk-antepartum score&quot;&#xD;
      or &quot;MOGGE PAR-A score&quot; in predicting potential outcomes once PAS is diagnosed antenatally. In&#xD;
      addition, it evaluates the validity of &quot;MOGGE placenta accreta risk-peripartum score&quot; or&#xD;
      &quot;MOGGE PAR-P score&quot; in calculating the probability of the same outcomes using baseline&#xD;
      features in conjugation with both disease-and surgery-related peripartum&#xD;
      variables,thereby,assist designation of the most suitable management. Finally , MOGGE CON-PAS&#xD;
      score was created for the subgroup of women who were subject to conservative management to&#xD;
      predict probability of uterine preservation success.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Incidence of PAS has significantly increased in concordance with rising trend of cesarean&#xD;
      section delivery (CS) among contemporary population.&#xD;
&#xD;
      Although cesarean hysterectomy, without trying to separate placenta (placenta in-situ), is&#xD;
      the standard management of PAS, uterine preservation may be routinely offered to women who&#xD;
      are concerned about preserving their uteri and may be considered the primary approach in many&#xD;
      institutes all over the world.&#xD;
&#xD;
      The &quot;Placenta Accreta Spectrum International Database (PAS-ID)&quot; is an international database&#xD;
      that was launched by Middle-East Obstetrics and Gynaecology Graduate Education (MOGGE)&#xD;
      Foundation to conduct the current study.&#xD;
&#xD;
      Eligible patients ,with criteria mentioned in following sections, will be counseled on&#xD;
      participation by one of the research team. They will be added to study database by an&#xD;
      independent investigator(observing investigator) who will collect baseline data and calculate&#xD;
      MOGGE PAR-A score using MOGGE PAR score 1.0 software (available at:&#xD;
      https://www.mogge-obgyn.com/clinical-studies). The observing investigator will continue to&#xD;
      collect clinical data in subsequent visits, through delivery and postpartum visit to&#xD;
      calculate MOGGE PAR-P score at the end of follow-up. If patient management involves a uterus&#xD;
      preserving procedure, MOGGE CON-PAS score will be calculated as well(it will be available at:&#xD;
      https://www.mogge-obgyn.com/clinical-studies). The observing investigator should not be a&#xD;
      part of patients'clinical care team, which should be blinded to the calculated scores. data&#xD;
      will be collected using an excel spreadsheet designed for this study. Concerned data include&#xD;
      patient age, parity, body mass index,smoking, ethnicity, previous gynecologic surgeries,&#xD;
      obstetric complications, gestational age at diagnosis and delivery(in weeks), method of&#xD;
      diagnosis, administration of antenatal steroids, indication of delivery, pre-delivery and&#xD;
      post-delivery hemoglobin (g/dl), operative management, placental site, degree of placental&#xD;
      invasion, type of cesarean incision and its relation to the placenta, intra-operative and&#xD;
      postoperative complications, intra-operative blood loss in ml, and transfusion of blood&#xD;
      products&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Number of women who experience placenta accreta spectrum related massive blood loss</measure>
    <time_frame>From skin incision to 24 hours postoperative (Total of 24 hours)</time_frame>
    <description>Blood loss &gt; 2500 ml or intra-operative disseminated intravscular coagulopathy (DIC) or transfusion of 10 or more packed red blood cell units</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of mothers admitted to intensive care unit</measure>
    <time_frame>From skin incision to 24 hours postoperative (Total of 24 hours)</time_frame>
    <description>Admission to intensive care unit after delivery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Days of maternal hospitalization after delivery</measure>
    <time_frame>From Cesarean delivery till hospital discharge (Assessment up to 6 weeks)</time_frame>
    <description>Maternal admission to hospital for more than 7 days after delivery</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Placenta Accreta Spectrum</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study comprises eligible women in 20 centers (anticipated), representing North-America,&#xD;
        South-America, Europe, Africa and Asia (all over the world)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women with suspected Placenta Accreta Spectrum (PAS),confirmed by clinical&#xD;
             and/ or histo-pathological findings.&#xD;
&#xD;
          -  They must be planned to deliver in one of centers recruited in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who reject participation or whose diagnosis with PAS is eventually excluded&#xD;
             based on clinical and/or histo-pathological findings.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherif A Shazly, M.Sc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherif A Shazly, M.Sc</last_name>
    <phone>+15075131392</phone>
    <email>sherif.shazly.mogge@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alaa HA Hegazy, M.Sc</last_name>
    <phone>+201221421220</phone>
    <email>alaa.hegazy.mogge@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Jauniaux E, Collins S, Burton GJ. Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. Am J Obstet Gynecol. 2018 Jan;218(1):75-87. doi: 10.1016/j.ajog.2017.05.067. Epub 2017 Jun 24. Review.</citation>
    <PMID>28599899</PMID>
  </reference>
  <reference>
    <citation>Silver RM, Branch DW. Placenta Accreta Spectrum. N Engl J Med. 2018 Apr 19;378(16):1529-1536. doi: 10.1056/NEJMcp1709324. Review.</citation>
    <PMID>29669225</PMID>
  </reference>
  <reference>
    <citation>Society of Gynecologic Oncology; American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine, Cahill AG, Beigi R, Heine RP, Silver RM, Wax JR. Placenta Accreta Spectrum. Am J Obstet Gynecol. 2018 Dec;219(6):B2-B16. doi: 10.1016/j.ajog.2018.09.042.</citation>
    <PMID>30471891</PMID>
  </reference>
  <reference>
    <citation>Cal M, Ayres-de-Campos D, Jauniaux E. International survey of practices used in the diagnosis and management of placenta accreta spectrum disorders. Int J Gynaecol Obstet. 2018 Mar;140(3):307-311. doi: 10.1002/ijgo.12391. Epub 2017 Dec 22.</citation>
    <PMID>29149470</PMID>
  </reference>
  <reference>
    <citation>Shazly SA, Hortu I, Shih JC, Melekoglu R, Fan S, Ahmed FUA, Karaman E, Fatkullin I, Pinto PV, Irianti S, Tochie JN, Abdelbadie AS, Ergenoglu AM, Yeniel AO, Sagol S, Itil IM, Kang J, Huang KY, Yilmaz E, Liang Y, Aziz H, Akhter T, Ambreen A, Ateş Ç, Karaman Y, Khasanov A, Larisa F, Akhmadeev N, Vatanina A, Machado AP, Montenegro N, Effendi JS, Suardi D, Pramatirta AY, Aziz MA, Siddiq A, Ofakem I, Dohbit JS, Fahmy MS, Anan MA; and Middle East Obstetrics and Gynecology Graduate Education (MOGGE) foundation - Artificial intelligence (AI) unit. Prediction of clinical outcomes in women with placenta accreta spectrum using machine learning models: an international multicenter study. J Matern Fetal Neonatal Med. 2021 Jul 7:1-10. doi: 10.1080/14767058.2021.1918670. [Epub ahead of print]</citation>
    <PMID>34233555</PMID>
  </reference>
  <reference>
    <citation>Mohri M, Rostamizadeh A, Talwalkar A: Foundations of machine learning: MIT press; 2018.</citation>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 19, 2020</study_first_submitted>
  <study_first_submitted_qc>August 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2020</study_first_posted>
  <last_update_submitted>August 21, 2020</last_update_submitted>
  <last_update_submitted_qc>August 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Sherif Abdelkarim Mohammed Shazly</investigator_full_name>
    <investigator_title>M.B.B.Ch, M.S.c in Gynecology and Obstetrics</investigator_title>
  </responsible_party>
  <keyword>cesarean section</keyword>
  <keyword>Uterine preservation</keyword>
  <keyword>MOGGE PAR score</keyword>
  <keyword>Hysterectomy</keyword>
  <keyword>Massive hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Placenta Accreta</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

